

# BIOGEN IDEC INC.

ISIN: US09062X1037 WKN: 09062X103 Asset Class: **Stock**

**Company** 2024/04/19 15:30:53

**Price**  
**190.22**  
USD

**Difference**  **-0.16%(-0.30)**



**Contact Details**

BIOGEN INC. Tel: +1-617-679-2000  
 -- Fax: +  
 225 Binney Street Web: <http://www.biogen.com>  
 02142 Cambridge E-mail: [info@biogen.com](mailto:info@biogen.com)

## Company Profile

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures                     | 2023           |                        | 2022           |                        | 2021           |                        |
|---------------------------------------|----------------|------------------------|----------------|------------------------|----------------|------------------------|
|                                       | Assets         | Liabilities and equity | Assets         | Liabilities and equity | Assets         | Liabilities and equity |
| <b>Current assets</b>                 | 6,859,300,000  |                        | 9,791,200,000  |                        | 7,856,500,000  |                        |
| <b>Common stock capital</b>           |                | 100,000                |                | 100,000                |                | 100,000                |
| <b>Fixed assets</b>                   | 19,985,500,000 |                        | 14,762,900,000 |                        | 16,020,800,000 |                        |
| <b>Equity capital of a company</b>    |                | 14,799,400,000         |                | 13,388,400,000         |                | 10,959,700,000         |
| <b>Cash and cash equivalents</b>      | 1,049,900,000  |                        | 3,419,300,000  |                        | 2,261,400,000  |                        |
| <b>Accrued liabilities</b>            |                | 0                      |                | 0                      |                | 0                      |
| <b>Other assets</b>                   | -              |                        | -              |                        | -              |                        |
| <b>Current liabilities</b>            |                | 3,434,300,000          |                | 3,272,800,000          |                | 4,298,200,000          |
| <b>Prepayments and accrued income</b> | -              |                        | -              |                        | -              |                        |
| <b>Non-current liabilities</b>        |                | 8,611,100,000          |                | 7,892,900,000          |                | 8,619,400,000          |
| <b>Different income</b>               |                | -                      |                | -                      |                | -                      |
| <b>Other liabilities</b>              |                | 781,100,000            |                | 944,200,000            |                | 1,320,500,000          |
| <b>Total assets</b>                   | 26,844,800,000 | 26,844,800,000         | 24,554,100,000 | 24,554,100,000         | 23,877,300,000 | 23,877,300,000         |

## Balance notes

|                            | 2023    | 2022    | 2021    |
|----------------------------|---------|---------|---------|
| <b>Accounting standard</b> | US-GAAP | US-GAAP | US-GAAP |
| <b>Employees</b>           | 7,570   | 8,725   | 9,610   |
| <b>Equity ratio</b>        | 55.13%  | 54.49%  | 46.17%  |
| <b>Debt-equity ratio</b>   | 81.39%  | 83.53%  | 116.61% |

## Others

|                         | 2023   | 2022   | 2021  |
|-------------------------|--------|--------|-------|
| <b>Tax Expense Rate</b> | 10.43% | 17.62% | 3.01% |

# BIOGEN IDEC INC.

ISIN: US09062X1037 WKN: 09062X103 Asset Class: **Stock**

## Income statement

|   | 2023          | 2022          | 2021           |
|---|---------------|---------------|----------------|
| Turnover  | 9,417,000,000 | 9,433,400,000 | 10,402,400,000 |
| Net income  | 1,161,100,000 | 3,046,900,000 | 1,556,100,000  |
| EBIT  | 1,213,628,240 | 3,546,253,920 | 1,905,892,560  |
| Operating income before taxes                                 | 1,296,800,000 | 3,591,800,000 | 1,745,200,000  |
| Cash Flow   | 1,547,200,000 | 1,384,300,000 | 3,639,900,000  |
| Net interest income   | 7,900,000     | -174,400,000  | -278,900,000   |
| Research and development expenses                             | 2,207,800,000 | 1,958,700,000 | 2,265,900,000  |
| Income taxes  | 135,300,000   | 632,800,000   | 52,500,000     |
| Result from investments in subsidiaries, associates and other | -             | 2,600,000     | 34,900,000     |
| Revenues per employee   | 1,171,340     | 1,018,050     | 1,019,240      |

## Board of Directors

## Members of Management Board

|                    |                                |
|--------------------|--------------------------------|
| Caroline Dorsa     | Chairman of Board of Directors |
| Eric Rowinsky      | Member of Board of Directors   |
| Maria Freire       | Member of Board of Directors   |
| Stephen Sherwin    | Member of Board of Directors   |
| Jesus Mantas       | Member of Board of Directors   |
| Monish Patolawala  | Member of Board of Directors   |
| Susan Langer       | Member of Board of Directors   |
| William Hawkins    | Member of Board of Directors   |
| Chris Viehbacher   | Chairman of Managing Board     |
| Ginger Gregory     | Member of Executive Committee  |
| Michael McDonnell  | Member of Executive Committee  |
| Nicole Murphy      | Member of Executive Committee  |
| Priya Singhal      | Member of Executive Committee  |
| Rachid Izzar       | Member of Executive Committee  |
| Susan H. Alexander | Member of Executive Committee  |